MONALEESA-3: A randomized double-blind, placebocontrolledstudy of ribociclib in combination withfulvestrant for the treatment of postmenopausal womenwith hormone receptor positive, HER2-negative, advancedbreast cancer who have received no or only one line ofprior endocrine treatment

Primary Objective

To compare PFS between ribociclib in combination with fulvestrant to placebo in combination with fulvestrant among postmenopausal women with HR+, HER2-negative advanced breast cancer who received no or only one prior endocrine treatment for advanced disease

This Study is
No Longer Enrolling

Details
Age

Adult

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Scope

National

Locations

Greeley Hospital
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital

Study ID

Protocol Number: 15-6019

More information available at ClinicalTrials.gov: NCT02422615

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers